• nl

4-Gn start-ups nominated

Four Start-Ups from Groninger are nominated for the “Academic Start-Up competition 2019”. Under them are 2 Carduso Capital participations CC Diagnostics and EV Biotech.

Read More

PIMS-E:

Carduso Capital invests in PIMS-E, a University of Groningen Spin-off developing an alternative for the Epipen™ via inhalation of Epinephrine by persons in a life-threatening reaction after exposure to an allergen that is dangerous to them. Think of insect stings such as from bees and wasps, food and drug allergies. The advantages of operation is the very short exposure time of dry-powder inhalation, one no longer has to give oneself an injection and the medicine has a long shelf life (and does not have to be kept in the refrigerator either).

PIMS-E did retrieve additional capital from the Carduso Capital investment fund for the development and commercialization of this Cyclops® dry powder inhalation. Dry powder inhalation is a method in which medicines are administered extremely efficiently through the lungs. The financing supports PIMS-E with the development, clinical testing and marketing of this new application.

The Cyclops® technology ensures optimum respiratory delivery of the medication in the purest form. This prevents unwanted side effects from excipients. PIMS-E sees the lungs as the ideal access to the systemic circulation for epinephrine. This route offers a number of advantages compared to the current most used application via the Epipen ™. The short exposure time and the non-invasive administration in combination with a longer shelf life at room temperature gives a greater ease of use and prevents the risk of puncture accidents.

PIMS-E is a pharmaceutical company based in Roden, The Netherlands, with in-house development and manufacturing capabilities and is established in collaboration with the University of Groningen’s Department of Pharmaceutical Technology and Biopharmacy of Professor Dr. H.W. Frijlink. Because of this unique partnership, PIMS-E possesses a skilled, enthusiastic and passionate team of researchers, pharmacists, pharmacy assistants, pharmaceutical professionals, QA/RA officials and product and process developers. For more information about PIMS-E, the director Reinier Schwietert can be contacted.

Carduso Capital is an investment firm based in Groningen, The Netherlands that participates in innovative technology companies that have strong technology links with the University of Groningen (RUG) and the University Medical Centre of Groningen (UMCG) and its affiliates. Carduso Capital believes it is important to invest in innovative companies that are early stage or at a certain moment search for capital to finance their growth. Carduso Capital supports initiatives within the main themes Life Sciences and Energy and aims for long-term cooperation’s. Besides participations with capital Carduso Capital also provides proactive management support and the use of its broad international network.

For more information about Carduso Capital: www.cardusocapital.com

Roden, Groningen, April 26 2019

For further information:

PIMS-E:
Mr. Reinier Schwietert
Tel: +31 (0) 6-51148308
Mail: rschwietert@pureims.com

Carduso Capital:
Mr. Frits Kok
Tel: +31 (0) 6-5375 1211
Mail: frits.kok@cardusocapital.com

Read More

EV Biotech kicks off, Investment from Carduso Capital, UMCG-Hanzepoort and RuG-Holding

Shifting the chemical market from petrochemical-based to biological-based compound production: a revolutionary step for a more sustainable world.

EV Biotech has been granted investments from Carduso Capital, in addition to the UMCG-Hanzepoort and RUG-Holding cooperation, to develop their microbial cell factories. EV Biotech creates micro-organism that effectively produce high value chemical compounds in a biological fashion. These organisms will be used for industrial scale production of these chemicals. The method EV Biotech uses to create their cell factories is revolutionary to the field. EV Biotech has created a digital laboratory to test all cell possibilities in advance, limiting time, waste, expenses and carbon footprint. A green and biological way to produce molecules used in Fragrance, Flavour, Pharma, Plastic, Agricultural and Fuel industries. 3 former PhD students from the University of Groningen founded the company

EV Biotech creates a new production platform for high value chemicals using computational modelling and micro-organisms. The production of the molecules will be biological, green and effective. The products made through this platform are of high purity, which is often hard to reach with chemical synthetic production. EV Biotech has been operational since July 2018 and is kicking off its laboratory activities now in the InnoLab AgriFood on the Campus Groningen. The technology used by EV Biotech creates a more sustainable production platform. EV Biotech has created a digital laboratory that can predict the most effective organism to produce specialty chemicals. Directly after the closing EV Biotech is strengthening its team to 6 people working on the developments.

“The investment in EV Biotech will allow the company to prove the effectiveness of their novel production pipeline by creating 4 proof of concept micro-organism factories which will be implemented into the market. EV Biotech serves the need of great chemical production firms. The investment together, with RUG-Holding and UMCG-Hanzepoort will help EV Biotech to break the petrochemical based chemical market to become bio-based.” Says Koos Koops, one of the Carduso fund managers. Founder and CEO Linda Dijkshoorn adds: “To reach a sustainable future we need to move away from chemical synthesis and use natures inventions to our advantage. Having 3 strong partners as investors will help us achieve this goal faster and more effectively.” EV Biotech will work on their proof of concepts in the coming two years to enter the market with their proof of concepts and start CRO activities.

For more information: www.evbio.tech

Patrick Brouns as representative of the province of Groningen, also a partner of Carduso Capital through its Investeringsfonds Groningen (IFG) says: “Because of the possibilities Carduso Capital has to offer new initiatives, potential ‘hidden gems’, will come to the surface and further energise the regional economic activity; one of our main goals with IFG.”

Carduso Capital is an investment fund based in Groningen that participates in innovative technology companies with strong technological connections with the University of Groningen (RUG) and the University Medical Center Groningen (UMCG) and knowledge institutions within its network. Carduso Capital considers it essential to invest in early stage, innovative companies; or companies that at some point need financing to continue growing. Carduso Capital supports initiatives within the areas of Life Sciences, Energy and Sustainability on the basis of long-term cooperation. In addition to financing, Carduso Capital offers management support and the possibility to use their worldwide international network. Investors in Carduso are: EIF, Investeringsfonds Groningen, NOM, De Friesland Participaties and RUG/UMCG.

For more info on Carduso Capital: www.cardusocapital.com

For further information :

EV Biotech:
Linda Dijkshoorn
Tel: +31(0) 6-50919901
Mail: l.dijkshoorn@evbio.tech

Carduso Capital:
Koos Koops
Tel: +31 (0) 6-22989098
Mail: koos.koops@cardusocapital.com

The EV Biotech team:

Carduso Capital participation ‘BioBTX’ and Teijin Aramid are looking at sustainable feedstock for super fiber.

Groningen, Nederland, 30 Oktober 2018

The Japanese company, Teijin Aramid, and the Dutch BioBTX are working on a synthetic fiber made entirely of sustainable materials. The initiative that is about to start is financially supported by the provinces of Drenthe and Groningen and by Chemport Europe. Teijin Aramid has production facilities in Emmen and Delfzijl. The initiative contributes to making the industry greener. It also strengthens the position of the Northern Netherlands chemical cluster, also known as Chemport Europe.

Teijin Aramid produces super strong fibers in the Netherlands under the brand name Twaron®. In the Netherlands, the company has facilities in, among others, Delfzijl and Emmen. Their fibers are used worldwide in products that need to be made stronger, lighter and more durable. For example, in car tires, light freight containers, and protective clothing. To produce Twaron® fossil resources are used for which there are currently no sustainable alternatives.

Site Manager, Edward Groen, from Teijin Aramid in Delfzijl explains that his company wants to examine the possibility of producing a so-called bio-based version of their Twaron® fiber. “Sustainability is an important subject for us. We are focused on both sustainability improvement by the application of our products in the chain with a lighter weight and longer lifespan, and reducing our CO2 footprint during production. In production the focus is on reducing energy flows and making them more sustainable. We’re also exploring possibilities for greener raw materials. It’s fantastic to do this scouting with a partner in Groningen.”

BioBTX

To develop a green feedstock Teijin Aramid works together with the company BioBTX in Groningen. This company developed a sustainable technology that can transform renewable resources, such as biomass and residual products, into chemical resources, mainly benzene, toluene, and xylene (BTX). With the BioBTX technology, it is possible to produce these so-called aromatics in a sustainable manner and, thus, largely reduce CO2 emissions. BioBTX recently opened a pilot plant to produce aromatics on the Zernike Campus in Groningen. Based on these aromatics the chemical company Syncom will produce specific building blocks. The polymer and fibers will be made in the Research Center at Teijin Aramid in Arnhem, based on the processes in Delfzijl and Emmen.

Pieter Imhof, CEO at BioBTX, responds enthusiastically. “We have already demonstrated that it is technically feasible to make bio-based BTX and polyester. Via this path and with the renowned Teijin Aramid, we want to demonstrate that it can also be used as a raw material for high-quality applications that have very strict quality requirements!”

Carduso participation Deam receives innovation award from Mona Keijzer, state secretary for economic affairs.

On 4 October, the no. 1 Eurostars Projects of the past 3 years were presented with an innovation award during the Innovation Expo 2018 in Rotterdam.

Read More

BioBTX commences operation of pilot plant for production of sustainable platform chemicals

Groningen, the Netherlands, September 13th, 2018

BioBTX B.V., a sustainable technology development company, today announced the official opening of the pilot plant for the production of sustainable platform chemicals in Groningen, the Netherlands.

BioBTX is developing a technology to convert non-food biomass and end-of-life feedstock materials into cornerstone aromatic chemicals, with a focus on Benzene, Toluene and Xylenes (“BTX”), which drop-in chemical intermediates are widely used for the production of plastics. By using renewable carbon sources, a significant contribution to the circular economy will be made, reducing the use of fossil feedstocks and lowering emission of greenhouse gases.

This pilot plant will initially convert non-food liquid biomass, like glycerol and fatty acids. In a second stage, the unit will be made suited to process solid biomass and end-of-life materials, like plastics and composites as well.

The pilot plant is located at Zernike Advance Processing (“ZAP”) site in Groningen the Netherlands, a semi-industrial environment with a focus on bio-based products, where knowledge institutions and businesses can take the important step from lab bench to medium scale production in green chemistry and biotechnology. Earlier this year, the offices of BioBTX have moved to this site, thus facilitating optimal communication and operation.

“We are excited that we can make this next step in commercialization of our technology following successful laboratory experiments in collaboration with the University of Groningen”, Pieter Imhof, CEO of BioBTX says.  “This is a milestone in our work to support the transition to a sustainable and circular economy. With this pilot plant we will be able to proof and optimize the technology, and provide samples to our partners for product and application research, for example by conversion into bio-based plastics.

The support of the shareholders as well as national (RVO), regional (SNN, Provinces of Groningen and Drenthe and municipality of Emmen) and European subsidies has enabled us to make this important step for our company.

We are looking forward to the outcomes from our pilot plant operation, which will allow us to commercialize our technology”.

About BioBTX B.V.

BioBTX B.V. is a sustainable technology development company. BioBTX is developing the ICCP (Integrated Cascading Catalytic Pyrolysis) technology for the cost competitive production of sustainable, aromatic chemical intermediates, like Benzene, Toluene, Xylenes, which are cornerstone chemicals for the production of plastics.

The technology is highly flexible with regards to feedstock materials, including non-food liquid and solid biomass as well as end-of-life materials.

The ICCP technology will contribute considerably to the circular economy making the chemical and plastics industry more sustainable.

BioBTX works with partners in the whole value to develop the technology

For further information contact:
Dr. Pieter Imhof, BioBTX B.V.
Tel: +31 (6) 5152 1179
Mail: pieter.imhof@biobtx.nl

Carduso Capital invests in “AGILeBiotics”

A breakthrough in the development of antibiotics against resistant bacteria

Carduso Capital invests in the Groningen start-up AGILeBiotics that is applying its platform technology, developing new antibiotics in the fast-growing markets of hospital-treated multidrug-resistant infections. The founding of AGILeBiotics is based on the worldwide patented platform ‘OxaSelect’, which gives quick access to various novel antibiotics based on an existing drug class. The technology was developed within the RUG. With OxaSelect a broad variety of drug candidates can be generated, leading to new antibiotics for the treatment of hospitalized patients infected by multidrug-resistant Gram-negative bacteria.

AGILeBiotics develops new antibiotics through a specific platform, called Oxaselect, and combining it with different synthetic steps to create the right molecule. Since March 2017, AGILeBiotics operates as an early-stage drug development company that focuses on the identification of novel antibiotic candidates based on aminoglycosides for clinical trials. The long-term goal of AGILeBiotics is to out-license novel drug candidates after clinical Phase IIA to the pharmaceutical industry. The proven technology OxaSelect allows rapid modification of existing aminoglycoside antibiotics avoiding the need for new target- and hit identification. In this way, novel antibiotics with improved safety profile and overcoming antibacterial resistance will be evolved by structure-based design in a much more cost- and timely efficient manner as performed in the pharmaceutical industry.

“By investing in AGILeBiotics a ground-breaking technology, invented at the RUG, is being applied for the development of novel antibiotics. Our investment, in this stage together with other RUG/UMCG bounded investment-initiatives, which will help this development against hospital-treated infections caused by bacteria that are resistant against current antibiotics.” says Koos Koops, one of the Carduso Fund managers. Founder and CEO Andreas A. Bastian, adds: “Due to the financial participation of Carduso Capital we have a long-term committed partner on board”. “AGILeBiotics is planning to develop a few candidates including clinical Phase studies in patients and that will take some years. All of this has provided us with the opportunity to further explore our promising technology.”

The province of Groningen is also a partner of Carduso Capital, through its Investeringsfonds Groningen (IFG). Representative Patrick Brouns says: “Because of the possibilities Carduso Capital has to offer new initiatives, potential ‘hidden gems’, will come to the surface and further energise the regional economic activity; one of our main goals with IFG.”

For more information:  www.AGILeBiotics.com

Carduso Capital is an investment fund based in Groningen that participates in innovative technology companies with strong technological connections with the University of Groningen (RUG) and the University Medical Center Groningen (UMCG) and knowledge institutions within its network. Carduso Capital considers it essential to invest in early stage, innovative companies; or companies that at some point need financing to continue growing. Carduso Capital supports initiatives within the areas of Life Sciences, Energy and Sustainability on the basis of long-term cooperation. In addition to financing, Carduso Capital offers management support and the possibility to use their worldwide international network. Investors in Carduso are: EIF, Investeringsfonds Groningen, NOM, De Friesland Participaties and RUG/UMCG.

For more info on Carduso Capital: www.cardusocapital.com

Groningen, 20th 2018.

For further information please contact:

AGILeBiotics:
Dr. Andreas Bastian
Tel: +31 (0) 6-39607999
Mail: a.a.bastian@agilebiotics.com

Carduso Capital:
Koos Koops
Tel: +31 (0) 6-22989098
Mail: koos.koops@cardusocapital.com

Carduso Capital invests in “CC Diagnostics”

A breakthrough in the early detection of cervical cancer screening

Carduso Capital invests in the Groningen start-up CC Diagnostics that is developing an unique test kit for detection of early stage cervical cancer. Cervical cancer is a worldwide problem, but in population-based screening programs the incidence of cervical cancers has decreased significantly in the last decades. With regular screening, the early precancerous changes in cervical cells can be detected and treated, and consequently preventing the development of cervical cancer. The founding of CC Diagnostics is based on a technology developed by dr. Bea Wisman, prof. dr. Ate van der Zee and prof. dr. Ed Schuuring from the University Medical Center Groningen (UMCG).

The currently used cytological PAP-test is world-wide the most common test method on cervical scrapings to identify women with an increased risk of developing cervical cancer, despite the PAP-test is less accurate than we would prefer and many false-positive cases. A cytological false-positive outcome indicates that a woman has cervical cancer, but in reality, after weeks of uncertainty and stress, examination by the gynaecologist shows no cancer. The new diagnostic test will potentially replace the current used cytological PAP-test. The new test will lead to a cost saving of at least 360 million euros of annual healthcare costs in Europe. As this test kit is also applicable on self-sampled material, the test kit enables women to participate in the cervical cancer screening from the comfort of their own homes, leading to a higher participation rate.

“By investing in CC Diagnostics a ground-breaking technology developed in the UMCG will reach the market. This company will increase the quality of our healthcare, as well as it helps to bring down unnecessary costs. This makes CC Diagnostics a great fit for Carduso Capital,” says Frits Kok, one of the Carduso Fund managers. Co-founder and CMO of CC Diagnostics, Drs. Nutte van Belzen, adds: “Due to the financial participation of Carduso Capital and the active support of the University Medical Center of Groningen’s departments of Gynaecologic Oncology and Pathology we can do the final testing of our technology and take the leap to the market. The Carduso Capital financial support also made it possible to receive a RVO-Innovation Credit. All of this has provided us with the opportunity to accelerate our promising technology.”
The province of Groningen is also a partner of Carduso Capital, through its Investeringsfonds Groningen (IFG). Representative Patrick Brouns says: “Because of the possibilities Carduso Capital has to offer new initiatives, potential ‘hidden gems’, will come to the surface and further energise the regional economic activity; one of our main goals with IFG.”

For more information: www.cc-diagnostics.com

Carduso Capital is an investment fund based in Groningen that participates in innovative technology companies with strong technological connections with the University of Groningen (RUG) and the University Medical Center Groningen (UMCG) and knowledge institutions within its network. Carduso Capital considers it essential to invest in early stage, innovative companies; or companies that at some point need financing to continue growing. Carduso Capital supports initiatives within the areas of Life Sciences, Energy and Sustainability on the basis of long-term cooperation. In addition to financing, Carduso Capital offers management support and the possibility to use their worldwide international network. Investors in Carduso are: EIF, Investeringsfonds Groningen, NOM, De Friesland Participaties and RUG/UMCG.

For more info on Carduso Capital: www.cardusocapital.com

Groningen, July 17th 2018.

For further information please contact:

CC Diagnostics:
Dhr. Drs. Nutte van Belzen
Tel: +31 (0) 6-44675768
Mail: n.van.belzen@cc-diagnostics.com

Carduso Capital:
Koos Koops
Tel: +31 (0) 6-22989098
Mail: koos.koops@cardusocapital.com

Read More

Carduso Capital invests in “Brainscan”

A potential breakthrough for diagnosing mental depressive disorder

BrainScan BV, based in Groningen (The Netherlands), is developing a ground-breaking technology for diagnosing mental depressive disorder (MDD). With the financing of Carduso Capital, BrainScan is now able to take her technology to the next level and bring it to the market. The company has a world-wide patent on its knowledge on measuring and interpreting biological markers in urine and blood that signal MDD. BrainScan has the ambition to measure the efficacy of treatment and medication given to patients with MDD, so that they are empowered in the process of choosing the right treatment. With the support of Carduso Capital, BrainScan will settle in the city of Groningen by the end of 2018 with four staff members. This will aid them in growing to twelve employees in the coming years and bringing their technology to the market.

“The impact of MDD on our society is becoming increasingly clear. GP’s are treating these types of patients more than ever, showing the importance of a prompt diagnosis. At this moment, patient intakes are conducted on the basis of clinical observation in combination with a standard questionnaire. The BrainScan objective laboratory test will increase the efficiency and quality of the patient intake, leading to a faster diagnosis and more personalised medication and therapy, benefitting a speedy recovery and reintegration into society. This potential for societal impact is why BrainScan is a great fit for Carduso Capital,” says Koos Koops, one of the Carduso Fund managers. Co-founder and CEO of BrainScan, Marc Meddens, adds: “Due to the financial participation of Carduso Capital and the active support of the University Medical Centre of Groningen’s departments of psychiatry and the General Medical Practice, we can do the final testing of our technology and take the leap to the free market. The Carduso financial support also made it possible to receive a RVO-Innovation Credit. All of this has provided us with the opportunity to accelerate our promising technology.”

The province of Groningen is also a partner of Carduso Capital, through its Investeringsfonds Groningen (IFG). Representative Patrick Brouns says: “because of the possibilities Carduso has to offer new initiatives, potential ‘hidden gems’, will come to the surface and further energise the regional economic activity; one of our main goals with IFG.”

BrainScan anticipates that its technology can lead to the identification of subtypes of depression. The diagnostic tool they are developing could lead to timely and substantiated choice of treatment and medication. For more information on BrainScan: www.brainscanbv.com

Carduso Capital is an investment fund based in Groningen that participates in innovative technology companies with strong technological connections with the University of Groningen (RUG) and the University Medical Center Groningen (UMCG) and knowledge institutions within its network. Carduso Capital considers it essential to invest in early stage, innovative companies; or companies that at some point need financing to continue growing. Carduso Capital supports initiatives within the areas of Life Sciences, Energy and Sustainability on the basis of long-term cooperation. In addition to financing, Carduso Capital offers management support and the possibility to use their worldwide international network. Investors in Carduso are: EIF, Investeringsfonds Groningen, NOM, De Friesland Participaties and RUG/UMCG.

For more info on Carduso Capital: www.cardusocapital.com

Groningen, January 26th 2018.

For further information please contact:

BrainScan:
Marc Meddens
Tel: +31 (0) 6-54264024
Mail: marcmeddens@brainscanbv.com

Carduso Capital:
Koos Koops
Tel: +31 (0) 6-22989098
Mail: koos.koops@cardusocapital.com

BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its € 1.0 million cardiac fibrosis imaging program.

Groningen, The Netherlands, December 14, 2017

An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac fibrosis imaging program is awarded to BiOrion Technologies BV. The grant will be used for the preparation and execution of a clinical phase 0 imaging study in cardiac fibrosis patients and the preclinical development of a targeted therapeutic, with BiOrion’s PDGF beta receptor binding bicyclic peptide conjugates. EFRO TENDER VALORISATIE 2017 is a program of the European Regional Development Fund from the European Commission, co-funded from the national budgets of Participating States, Partner Countries and by the European Union through Horizon 2020.


Herman Steen, CEO of BiOrion, said “This European Union EFRO grant will further enable BiOrion to progress its clinical development of its novel myofibroblast targeting platform. It is an ongoing recognition and support for our PDGF-beta-receptor binding bicyclic peptide drug-conjugates technology.”

About BiOrion Technologies
BiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007, engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic
diseases. These diseases include cardiac fibrosis, hepatic fibrosis, and fibrosis-associated cancers such as colorectal cancer. BiOrion’s platform and drug development engine is based on proprietary PDGF-beta-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET radionuclides and (existing) anti-fibrotic therapeutics.

Contact
Herman Steen, PhD
CEO BiOrion Technologies BV
herman.steen@biorion.com